Company Filing History:
Years Active: 2007-2019
Title: Annemieke Geluk: Innovator in Immunology
Introduction
Annemieke Geluk is a prominent inventor based in Woubrugge, Netherlands. She has made significant contributions to the field of immunology, particularly in the development of peptide-based vaccines. With a total of 4 patents, her work focuses on enhancing antigen-specific immune responses.
Latest Patents
Her latest patents include innovative long peptides of 22-45 amino acid residues that induce and enhance antigen-specific immune responses. These peptides are derived from human papilloma virus and are designed to immunize subjects against (Myco) bacterially and/or virally infected cells or tumor cells. The peptide sequences of 22-35 amino acid residues can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Furthermore, vaccination with these longer peptides results in a more vigorous CD8+ cytolytic T-cell response compared to vaccination with peptides of the exact minimal CTL epitope length. This research also addresses the challenges posed by certain minimal CTL epitopes that can tolerize cytolytic cells instead of activating them. Clinically relevant approaches for vaccination and treatment against HPV and methods for treating subjects suffering from progressive lesions and cervical cancer are also disclosed in her patents.
Career Highlights
Annemieke Geluk is affiliated with Academisch Ziekenhuis Leiden, where she continues her research and development in immunology. Her work has garnered attention for its potential impact on vaccine development and cancer treatment.
Collaborations
She collaborates with notable colleagues such as Sjoerd Hendrikus Van Der Burg and Maria Johanna Philomena Schoenmaekers-Welters, contributing to a dynamic research environment.
Conclusion
Annemieke Geluk's innovative work in the field of immunology, particularly her advancements in peptide-based vaccines, positions her as a key figure in the ongoing fight against viral infections and cancer. Her contributions are paving the way for future breakthroughs in immunotherapy.